Focused Agreement is on Therapeutic Area of Mutual Interest
NEW YORK--(BUSINESS WIRE)--Apr. 23, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical
company developing treatments to address unmet needs in the field of
uro-oncology, today announced that it has entered into an agreement with
Janssen Research & Development, LLC (Janssen) to conduct an early-stage
feasibility evaluation in a therapeutic area of mutual interest. UroGen
and Janssen will each conduct certain activities under the terms of the
agreement.
“We are excited to enter into this agreement with Janssen, an industry
leader with a history of developing transformative therapies,” said Liz
Barrett, President and Chief Executive Officer of UroGen. “We maintain a
strong commitment to bringing innovative treatments to patients in areas
of unmet need.”
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™ reverse-thermal hydrogel, a proprietary sustained
release, hydrogel-based platform technology that has the potential to
improve therapeutic profiles of existing drugs. UroGen’s sustained
release technology is designed to enable longer exposure of the urinary
tract tissue to medications, making local therapy a potentially more
effective treatment option. UroGen’s lead investigational candidates,
UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel)
for intravesical instillation, are designed to potentially ablate tumors
by non-surgical means and to treat several forms of non-muscle invasive
urothelial cancer, including low-grade upper tract urothelial cancer and
low-grade non-muscle invasive bladder cancer, respectively. UroGen is
headquartered in New York, NY with operations in Los Angeles, CA and
Israel.
Forward Looking Statements
This press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including plans to conduct an early stage feasibility evaluation, the
potential of UGN-101 for LG UTUC, the potential of UroGen’s proprietary
RTGel™ technology platform to improve therapeutic profiles of existing
drugs, and the potential of UGN-102 for LG NMIBC, which statements are
subject to a number of risks, uncertainties and assumptions, including,
but not limited to: the timing and success of clinical trials, including
the Olympus pivotal Phase 3 trial and potential safety and other
complications thereof; the ability to obtain and maintain regulatory
approval; the labeling for any approved product; the scope, progress and
expansion of developing and commercializing UroGen Pharma’s product
candidates; the size and growth of the market(s) therefor and the rate
and degree of market acceptance thereof vis-à-vis alternative therapies;
and UroGen Pharma’s ability to attract or retain key management, members
of the board of directors and personnel. In light of these risks and
uncertainties, and other risks and uncertainties that are described in
the Risk Factors section of UroGen Pharma’s Form 10-K filed with the SEC
on February 28, 2019 and other filings that UroGen Pharma makes with the
SEC from time to time (which are available at http://www.sec.gov),
the events and circumstances discussed in such forward-looking
statements may not occur, and UroGen Pharma’s actual results could
differ materially and adversely from those anticipated or implied
thereby. Any forward-looking statements speak only as of the date of
this press release and are based on information available to UroGen
Pharma as of the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005292/en/
Source: UroGen Pharma Ltd.
Media:
UROGEN:
Kate Bechtold
Director, Corporate
Communications & Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
